Center for Biosimilars8d
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 ...
Managed Healthcare Executive10d
The Biosimilars Report Card
It has been 10 years since the first biosimilar was approved by the FDA. The grades on how the market for biosimilars has ...
pharmaphorum7y
Amgen fails to block Neupogen biosimilar
The biosimilar – called Zarxio – was the first biosimilar to be approved for marketing in the US earlier this month although it has been on sale elsewhere for many years, debuting in the EU in ...
pharmaphorum3d
5 years of biosimilars in the US: what have we learned?
This year marks the five-year anniversary since the first biosimilar, Sandoz’s Zarxio, was introduced in the United States. We anticipate that 2020 will be the most pivotal year yet for the ...